The pharmacokinetics of racemic verapamil in patients with impaired renal function

P. K. Zachariah, T. P. Moyer, H. M. Theobald, Robert Frantz, S. B. Kurtz, J. T. McCarthy, R. L. Smith

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The pharmacokinetics of verapamil were studied in patients with renal failure who were undergoing maintenance hemodialysis and in normal subjects after an IV infusion of 10 mg and a single oral dose of 120 mg. Plasma levels of verapamil and its active metabolite, norverapamil, were analyzed by a sensitive and specific HPLC procedure. Severe renal failure requiring hemodialysis did not change the time course of verapamil and norverapamil plasma concentrations after either the IV or oral dose. The terminal elimination rate constant, clearance, volume of distribution, and bioavailability of verapamil were not significantly different between the two groups of subjects. In addition, the apparent maximal plasma concentration, terminal elimination rate constant, and area under the curve for norverapamil were similar in patients with renal failure and normal subjects. The study showed that the plasma disposition of verapamil and norverapamil was not affected in patients with impaired renal function. Furthermore, this study does not indicate that any change in dosage is necessary when single doses of verapamil are administered to patients with renal failure.

Original languageEnglish (US)
Pages (from-to)45-53
Number of pages9
JournalJournal of Clinical Pharmacology
Volume31
Issue number1
StatePublished - 1991

Fingerprint

Verapamil
Pharmacokinetics
Kidney
Renal Insufficiency
Renal Dialysis
Biological Availability
Area Under Curve
High Pressure Liquid Chromatography
Maintenance
norverapamil

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Zachariah, P. K., Moyer, T. P., Theobald, H. M., Frantz, R., Kurtz, S. B., McCarthy, J. T., & Smith, R. L. (1991). The pharmacokinetics of racemic verapamil in patients with impaired renal function. Journal of Clinical Pharmacology, 31(1), 45-53.

The pharmacokinetics of racemic verapamil in patients with impaired renal function. / Zachariah, P. K.; Moyer, T. P.; Theobald, H. M.; Frantz, Robert; Kurtz, S. B.; McCarthy, J. T.; Smith, R. L.

In: Journal of Clinical Pharmacology, Vol. 31, No. 1, 1991, p. 45-53.

Research output: Contribution to journalArticle

Zachariah, PK, Moyer, TP, Theobald, HM, Frantz, R, Kurtz, SB, McCarthy, JT & Smith, RL 1991, 'The pharmacokinetics of racemic verapamil in patients with impaired renal function', Journal of Clinical Pharmacology, vol. 31, no. 1, pp. 45-53.
Zachariah PK, Moyer TP, Theobald HM, Frantz R, Kurtz SB, McCarthy JT et al. The pharmacokinetics of racemic verapamil in patients with impaired renal function. Journal of Clinical Pharmacology. 1991;31(1):45-53.
Zachariah, P. K. ; Moyer, T. P. ; Theobald, H. M. ; Frantz, Robert ; Kurtz, S. B. ; McCarthy, J. T. ; Smith, R. L. / The pharmacokinetics of racemic verapamil in patients with impaired renal function. In: Journal of Clinical Pharmacology. 1991 ; Vol. 31, No. 1. pp. 45-53.
@article{bac1643562304c1789e9d9767b80e13c,
title = "The pharmacokinetics of racemic verapamil in patients with impaired renal function",
abstract = "The pharmacokinetics of verapamil were studied in patients with renal failure who were undergoing maintenance hemodialysis and in normal subjects after an IV infusion of 10 mg and a single oral dose of 120 mg. Plasma levels of verapamil and its active metabolite, norverapamil, were analyzed by a sensitive and specific HPLC procedure. Severe renal failure requiring hemodialysis did not change the time course of verapamil and norverapamil plasma concentrations after either the IV or oral dose. The terminal elimination rate constant, clearance, volume of distribution, and bioavailability of verapamil were not significantly different between the two groups of subjects. In addition, the apparent maximal plasma concentration, terminal elimination rate constant, and area under the curve for norverapamil were similar in patients with renal failure and normal subjects. The study showed that the plasma disposition of verapamil and norverapamil was not affected in patients with impaired renal function. Furthermore, this study does not indicate that any change in dosage is necessary when single doses of verapamil are administered to patients with renal failure.",
author = "Zachariah, {P. K.} and Moyer, {T. P.} and Theobald, {H. M.} and Robert Frantz and Kurtz, {S. B.} and McCarthy, {J. T.} and Smith, {R. L.}",
year = "1991",
language = "English (US)",
volume = "31",
pages = "45--53",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - The pharmacokinetics of racemic verapamil in patients with impaired renal function

AU - Zachariah, P. K.

AU - Moyer, T. P.

AU - Theobald, H. M.

AU - Frantz, Robert

AU - Kurtz, S. B.

AU - McCarthy, J. T.

AU - Smith, R. L.

PY - 1991

Y1 - 1991

N2 - The pharmacokinetics of verapamil were studied in patients with renal failure who were undergoing maintenance hemodialysis and in normal subjects after an IV infusion of 10 mg and a single oral dose of 120 mg. Plasma levels of verapamil and its active metabolite, norverapamil, were analyzed by a sensitive and specific HPLC procedure. Severe renal failure requiring hemodialysis did not change the time course of verapamil and norverapamil plasma concentrations after either the IV or oral dose. The terminal elimination rate constant, clearance, volume of distribution, and bioavailability of verapamil were not significantly different between the two groups of subjects. In addition, the apparent maximal plasma concentration, terminal elimination rate constant, and area under the curve for norverapamil were similar in patients with renal failure and normal subjects. The study showed that the plasma disposition of verapamil and norverapamil was not affected in patients with impaired renal function. Furthermore, this study does not indicate that any change in dosage is necessary when single doses of verapamil are administered to patients with renal failure.

AB - The pharmacokinetics of verapamil were studied in patients with renal failure who were undergoing maintenance hemodialysis and in normal subjects after an IV infusion of 10 mg and a single oral dose of 120 mg. Plasma levels of verapamil and its active metabolite, norverapamil, were analyzed by a sensitive and specific HPLC procedure. Severe renal failure requiring hemodialysis did not change the time course of verapamil and norverapamil plasma concentrations after either the IV or oral dose. The terminal elimination rate constant, clearance, volume of distribution, and bioavailability of verapamil were not significantly different between the two groups of subjects. In addition, the apparent maximal plasma concentration, terminal elimination rate constant, and area under the curve for norverapamil were similar in patients with renal failure and normal subjects. The study showed that the plasma disposition of verapamil and norverapamil was not affected in patients with impaired renal function. Furthermore, this study does not indicate that any change in dosage is necessary when single doses of verapamil are administered to patients with renal failure.

UR - http://www.scopus.com/inward/record.url?scp=0026029423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026029423&partnerID=8YFLogxK

M3 - Article

C2 - 2045528

AN - SCOPUS:0026029423

VL - 31

SP - 45

EP - 53

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 1

ER -